INT5870

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1985
Last Reported 2010
Negated 2
Speculated 0
Reported most in Abstract
Documents 20
Total Number 20
Disease Relevance 12.00
Pain Relevance 4.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IFNA2) extracellular region (IFNA2) cell-cell signaling (IFNA2)
Anatomy Link Frequency
leucocyte 1
peritoneal cavity 1
B-cell 1
lymphocyte 1
mast cell 1
IFNA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 16 100.00 Very High Very High Very High
Paracetamol 6 99.80 Very High Very High Very High
aspirin 13 99.42 Very High Very High Very High
Analgesic 16 97.36 Very High Very High Very High
Substantia nigra 2 96.80 Very High Very High Very High
Hippocampus 2 96.08 Very High Very High Very High
antagonist 1 95.00 High High
withdrawal 3 94.92 High High
abdominal pain 4 94.60 High High
opioid receptor 3 94.56 High High
Disease Link Frequency Relevance Heat
Ovarian Cancer 9 99.84 Very High Very High Very High
Toxicity 6 99.60 Very High Very High Very High
Adhesions 1 99.36 Very High Very High Very High
Pressure And Volume Under Development 5 99.26 Very High Very High Very High
Vesicular Stomatitis 2 98.64 Very High Very High Very High
Systemic Mastocytosis 14 98.00 Very High Very High Very High
Herpes Zoster 159 97.66 Very High Very High Very High
Immunodeficiency 2 97.40 Very High Very High Very High
Mast Cell Leukemia 2 96.92 Very High Very High Very High
Intestinal Obstruction 1 96.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The combination of IFN-alpha and hydroxyurea is very useful and allows dosage reduction of IFN-alpha and better control of hypereosinophilia than with either agent alone.
Negative_regulation (reduction) of IFN-alpha
1) Confidence 0.49 Published 2005 Journal Acta Haematol. Section Abstract Doc Link 15995323 Disease Relevance 0.84 Pain Relevance 0.04
It was concluded that neither indomethacin, aspirin, nor acetaminophen directly inhibited the antiviral and antiproliferative activities of rIFN-alpha 2a.
Negative_regulation (inhibited) of rIFN-alpha 2a associated with aspirin and paracetamol
2) Confidence 0.43 Published 1988 Journal J. Interferon Res. Section Abstract Doc Link 3230331 Disease Relevance 0.26 Pain Relevance 0.42
None of the drugs inhibited the antiviral activity of rIFN-alpha 2a in human amnion FL cells against vesicular stomatitis virus, or interfered with its antiproliferative activity against acute lymphoblastic leukemia MOLT-4 cells or renal cell carcinoma NC 65 cells.
Negative_regulation (inhibited) of rIFN-alpha 2a in MOLT-4 associated with leukemia, vesicular stomatitis and renal cancer
3) Confidence 0.43 Published 1988 Journal J. Interferon Res. Section Abstract Doc Link 3230331 Disease Relevance 0.29 Pain Relevance 0.39
The inhibitory effect of hrIFN alpha is sensitive to temperature with maximum inhibition observed at 37 degrees C, and less as incubation temperature is reduced.
Negative_regulation (effect) of hrIFN alpha
4) Confidence 0.43 Published 1992 Journal Life Sci. Section Abstract Doc Link 1317938 Disease Relevance 0 Pain Relevance 0.47
However, although the antiviral activity of IFNalpha decreased to 34.1% of wild type IFNalpha after the 122nd Tyr residue was changed to Ser, the analgesic activity of this mutant was lost completely.
Negative_regulation (decreased) of IFNalpha associated with analgesic
5) Confidence 0.42 Published 2000 Journal J. Neuroimmunol. Section Abstract Doc Link 10900338 Disease Relevance 0 Pain Relevance 0.92
It was concluded that the formation of ascites in refractory ovarian cancer can be reduced with intraperitoneal administration of interferon alpha-2b and mitoxantrone, with tolerable side effects.
Negative_regulation (reduced) of interferon alpha-2b associated with pressure and volume under development and ovarian cancer
6) Confidence 0.42 Published 1994 Journal Ann Chir Gynaecol Suppl Section Abstract Doc Link 8092765 Disease Relevance 1.08 Pain Relevance 0.09
Fourteen patients with persistent epithelial ovarian cancer documented at second look laparotomy after combination chemotherapy were treated with 146 cycles of alpha-recombinant interferon (rIFN-alpha 2) administered i.p.
Negative_regulation (cycles) of alpha-recombinant interferon associated with ovarian cancer
7) Confidence 0.42 Published 1985 Journal Cancer Res. Section Abstract Doc Link 4028027 Disease Relevance 0.37 Pain Relevance 0
Fourteen patients with persistent epithelial ovarian cancer documented at second look laparotomy after combination chemotherapy were treated with 146 cycles of alpha-recombinant interferon (rIFN-alpha 2) administered i.p.
Negative_regulation (cycles) of rIFN-alpha 2 associated with ovarian cancer
8) Confidence 0.42 Published 1985 Journal Cancer Res. Section Abstract Doc Link 4028027 Disease Relevance 0.37 Pain Relevance 0
In summary, our data confirm beneficial effects of IFN-alpha2b (plus prednisolone) for a group of patients with ASM, whereas patients with mast cell leukemia may require more aggressive therapy.
Negative_regulation (effects) of IFN-alpha2b in mast cell associated with systemic mastocytosis and mast cell leukemia
9) Confidence 0.41 Published 2004 Journal Leuk. Res. Section Abstract Doc Link 14687620 Disease Relevance 0.82 Pain Relevance 0
Patients received 18 X 10(6) units interferon alpha-2a by i.m. injection daily for the first 10 weeks and then three times weekly for a further 4 months.
Negative_regulation (received) of interferon alpha-2a
10) Confidence 0.29 Published 1987 Journal J. Cancer Res. Clin. Oncol. Section Abstract Doc Link 3584216 Disease Relevance 1.16 Pain Relevance 0.08
Continuation therapy including rIFN-alpha pulse was well tolerated in the remaining children; only one patient required rIFN-alpha dosage reduction (for CNS toxicity). rIFN-alpha toxicity did not necessitate reductions in doses of standard chemotherapy agents or significant delays in therapy.
Negative_regulation (reduction) of rIFN-alpha associated with toxicity
11) Confidence 0.21 Published 1991 Journal J. Clin. Oncol. Section Abstract Doc Link 2016619 Disease Relevance 0.95 Pain Relevance 0.08
However, increases were not significantly different between patients receiving IL-2 alone and IL-2 plus IFN-alpha.
Negative_regulation (receiving) of IFN-alpha
12) Confidence 0.21 Published 1993 Journal Cancer Res. Section Abstract Doc Link 8443808 Disease Relevance 0.26 Pain Relevance 0.09
Zoster is the result of reactivation of latent VZV and transport to basal epidermis of skin where infected cells produce conditions favoring virus spread, such as the downregulation of interferon-alpha and lymphocyte adhesion molecules (Ku et al 2004).
Negative_regulation (downregulation) of interferon-alpha in lymphocyte associated with herpes zoster and adhesions
13) Confidence 0.13 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2374947 Disease Relevance 1.45 Pain Relevance 0
The treatment options for B-cell PTLDs include reduction of immunosuppression, antiviral therapy, interferon alpha therapy, CD20 antibody therapy and chemotherapy.
Negative_regulation (reduction) of interferon alpha in B-cell
14) Confidence 0.10 Published 2010 Journal Diagn Pathol Section Body Doc Link PMC2853499 Disease Relevance 2.12 Pain Relevance 0.03
The full dose of leucocyte IFN-alpha, when used in patients previously intolerant to the same dosage of lymphoblastoid IFN-alpha, was better tolerated: only one of the 15 patients who completed the 12-month treatment had a severe adverse event leading to withdrawal vs 22 of 68 patients treated with lymphoblastoid IFN-alpha.
Negative_regulation (dosage) of IFN-alpha in leucocyte associated with withdrawal
15) Confidence 0.10 Published 1998 Journal J. Viral Hepat. Section Abstract Doc Link 9795917 Disease Relevance 0.63 Pain Relevance 0.13
During low-dose IL-2 treatment, patients received IFN-alpha 5 x 10(6) U/m2/day on days 1 and 4 of each week.
Negative_regulation (received) of IFN-alpha
16) Confidence 0.04 Published 1992 Journal J. Immunother. Section Abstract Doc Link 1322167 Disease Relevance 0.66 Pain Relevance 0.08
Its immunosuppressive effect was further demonstrated by inhibition of interleukin-9 (IL-9), IL-10 but failed to influence IL-2, IL-15 and interferon-y (IFN-gamma) in PPD stimulated human PBMCs.
Neg (failed) Negative_regulation (influence) of interferon-y
17) Confidence 0.02 Published 2002 Journal Int. Immunopharmacol. Section Abstract Doc Link 12095165 Disease Relevance 0.08 Pain Relevance 0.37
The activity of rHu-IL-1 alpha and rHu-TNF, unlike mIFN alpha, was not naloxone-reversible. rHu-IL-1 alpha did not produce an increase in writhes counts even if injected directly into the peritoneal cavity.
Neg (not) Negative_regulation (naloxone-reversible) of mIFN alpha in peritoneal cavity associated with narcan
18) Confidence 0.02 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3260869 Disease Relevance 0.38 Pain Relevance 0.40
The behavioural and ECoG effects of alpha-interferon, rat interferon and interleukin-2 were blocked in animals pretreated with naloxone.
Negative_regulation (blocked) of alpha-interferon associated with narcan
19) Confidence 0.01 Published 1990 Journal Ann. Ist. Super. Sanita Section Abstract Doc Link 2393221 Disease Relevance 0.14 Pain Relevance 0.35
The behavioural and ECoG effects of alpha-interferon, rat interferon and interleukin-2 were blocked in animals pretreated with naloxone.
Negative_regulation (blocked) of alpha-interferon associated with narcan
20) Confidence 0.01 Published 1990 Journal Neuropharmacology Section Abstract Doc Link 1691831 Disease Relevance 0.14 Pain Relevance 0.35

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox